PrEP for people who use opioids: A NIDA clinical trials network survey study in Southern U.S. cities where HIV incidence is high
03/2024
Journal Article
Authors:
Hatch, M. A.;
Laschober, T. C.;
Paschen-Wolff, M.;
Ertl, M. M.;
Nelson, C. M.;
Wright, L.;
Lancaster, C.;
Feaster, D. J.;
Forrest, D.;
Hankey, C.;
Monger, M.;
Fegley, J. P.;
Irving, R.;
Young, C.;
Rose, J.;
Spector, A.;
Dresser, L.;
Moran, L.;
Jelstrom, E.;
Tross, S.
Volume:
257
Journal:
Drug Alcohol Depend
PMID:
38447393
URL:
https://pubmed.ncbi.nlm.nih.gov/38447393/
DOI:
10.1016/j.drugalcdep.2024.111133
Keywords:
Male Female Humans Homosexuality, Male Cities Cross-Sectional Studies Incidence Analgesics, Opioid/therapeutic use *HIV Infections/epidemiology/prevention & control/drug therapy *Sexual and Gender Minorities
*Pre-Exposure Prophylaxis Patient Acceptance of Health Care *Anti-HIV Agents/therapeutic use *Nitrosamines HIV risk Opioid use PrEP Southeastern United States Substance use
Abstract:
BACKGROUND: People who use opioids (PWUO) are at increased risk for HIV. Pre-exposure prophylaxis (PrEP) is effective but underutilized as HIV prevention among PWUO. This study examined predictors of willingness to take daily oral PrEP and long-acting injectable (LAI) PrEP among PWUO across eight Southern urban cities with high HIV incidence. METHODS: HIV-negative PWUO (N = 308) seeking services in community-based programs participated in this cross-sectional survey study. Measures included demographics, sexual risk behavior, substance use frequency, and awareness of and willingness to take oral and injectable PrEP. Data were analyzed using mixed-effects models. RESULTS: Willingness to take daily oral and LAI PrEP was moderately high (69.16% and 62.02%, respectively). Half had heard of PrEP, but only 4% had ever taken it. Only education and condomless vaginal sex predicted willingness to take oral PrEP. Only education predicted willingness to take LAI PrEP. Polysubstance use was prevalent, with substantial proportions of PWUO reporting frequent use of injection drugs (opioids or stimulants, 79.5%), non-injection opioids (73.3%), non-injection stimulants (71.1%), cannabis (62.6%), and hazardous drinking (29.6%). About 20% reported past-year condomless anal sex, and one-third reported past-year condomless vaginal sex. CONCLUSIONS: PWUO in this study were amenable to PrEP, particularly in light of education and condomless vaginal sex. Careful consideration for matching PrEP messaging to the PWUO audience is needed. PrEP promotion should expand beyond men who have sex with men to include groups such as these predominantly heterosexual, polysubstance-using PWUO with HIV risk who were open to both formulations of PrEP.
